-+ 0.00%
-+ 0.00%
-+ 0.00%

iBio Initiates Non-human Primate Study For Its Activin E Engineered Antibody Candidate, Now Named IBIO-610. This Preclinical Study Will Evaluate The Pharmacokinetics And Early Signs Of Efficacy Of IBIO-610 In Obese And Elderly NHPs, Including Its Impact On Fat And Body Composition

Benzinga·06/16/2025 11:06:49
Listen to the news
  • iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody
  • New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition
  • Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd